The SYNBioSe Study A proof-of-concept study involving synergetic B-cell imunnomodulation in patients with refractory systemic lupus erythematosus

Trial Profile

The SYNBioSe Study A proof-of-concept study involving synergetic B-cell imunnomodulation in patients with refractory systemic lupus erythematosus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Belimumab (Primary) ; Rituximab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Synbiose
  • Most Recent Events

    • 03 Jul 2017 New trial record
    • 17 Jun 2017 Results (n=11) presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 17 Jun 2017 Results (n=10) presented at the 18th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top